| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Immunovant, Inc. | Director | Common Stock | 25K | $367K | $14.68 | May 1, 2025 | Direct |
| BridgeBio Oncology Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 138K | Aug 26, 2025 | Direct | ||
| Immunovant, Inc. | Director | Stock Option (Right to Buy) | 35.2K | May 1, 2025 | Direct | ||
| Enliven Therapeutics, Inc. | Director | Stock Option (right to buy) | 20.5K | Feb 6, 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| BBOT | BridgeBio Oncology Therapeutics, Inc. | Aug 26, 2025 | 1 | $0 | 4 | Aug 28, 2025 | Director |
| BBOT | BridgeBio Oncology Therapeutics, Inc. | Aug 11, 2025 | 0 | $0 | 3 | Aug 18, 2025 | Director |
| IMVT | Immunovant, Inc. | May 1, 2025 | 2 | $0 | 4 | May 5, 2025 | Director |
| IMVT | Immunovant, Inc. | Apr 18, 2025 | 0 | $0 | 3 | Apr 28, 2025 | Director |
| ELVN | Enliven Therapeutics, Inc. | Feb 6, 2025 | 1 | $0 | 4 | Feb 10, 2025 | Director |
| ELVN | Enliven Therapeutics, Inc. | Feb 13, 2024 | 1 | $0 | 4/A | Feb 20, 2024 | Director |
| ELVN | Enliven Therapeutics, Inc. | Feb 13, 2024 | 1 | $0 | 4 | Feb 15, 2024 | Director |
| ELVN | Enliven Therapeutics, Inc. | Feb 23, 2023 | 1 | $0 | 4 | Apr 6, 2023 | Director |
| ELVN | Enliven Therapeutics, Inc. | Feb 23, 2023 | 2 | $0 | 4 | Feb 27, 2023 | Director |
| ELVN | Enliven Therapeutics, Inc. | Feb 23, 2023 | 0 | $0 | 3 | Feb 27, 2023 | Director |
| ARYE | ARYA Sciences Acquisition Corp V | Jul 12, 2021 | 0 | $0 | 3 | Jul 12, 2021 | Director |